Back to search results

Chloroquine for Persistent Atrial Fibrillation

This study is looking at whether chloroquine phosphate can help stop persistent atrial fibrillation (AF), which is an irregular and often rapid heartbeat lasting more than 7 days. The goal is to see if chloroquine phosphate can act as a treatment to return the heart to a normal rhythm. You may be able to join if you are 18 years or older and have symptomatic persistent AF. The study will measure how many patients have their AF stop within two weeks of starting the medication. The current status of this study is unclear, and it plans to enroll 40 participants.

Study design
This is an open-label pilot study, meaning both you and the study team will know you are receiving chloroquine phosphate. It plans to include 40 participants.
What's involved
You would take two tablets of chloroquine phosphate on the first day and the next, then one tablet daily for 12 more days. The medication is taken by mouth with food.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for two weeks from the start of taking the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02932007

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

Recruiting
PHASE2Ages 18+InterventionalTreatment
University of South Florida
~40 participants
Updated 2019-08-19 on ClinicalTrials.gov
What's tested:Chloroquine Phosphate

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of patients with termination of AF
Measured over Within 2 weeks of study drug initiation

Conditions

Atrial Fibrillation

Explore related trials

Atrial Fibrillation

NCT02932007

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of South Florida

    Tampa, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Sami Noujaim, PhD · PRINCIPAL_INVESTIGATOR · University of South Florida

Who to contact

Thanh Tran, MPH
[email protected]
813-844-8544
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

are pregnant or breast-feeding or plan to become pregnant during study or
who are not surgically sterile and are not practicing two acceptable methods of birth control, or do not plan to continue practicing two acceptable methods of birth control throughout the study (highly effective methods are listed under section 6.0 Pregnancy) 18. Current participation in another clinical study 19. Serious or active medical or psychiatric condition which, in the opinion of the investigator, may interfere with treatment, assessment, or compliance with the protocol 20. Not able to discontinue medications known to have significant interactions with chloroquine

What this trial measures

  • Proportion of patients with termination of AFWithin 2 weeks of study drug initiation